[{"id":"f01e63ff-cabb-4f43-915d-19172e8beeed","acronym":"","url":"https://clinicaltrials.gov/study/NCT02031744","created_at":"2021-01-18T09:19:00.776Z","updated_at":"2024-07-02T16:37:24.418Z","phase":"Phase 3","brief_title":"A Study of the Efficacy and Safety of MetMAb Combined With Tarceva in Patients With Met-Positive Non-Small Cell Lung Cancer","source_id_and_acronym":"NCT02031744","lead_sponsor":"Hoffmann-La Roche","biomarkers":" EGFR","pipe":" | ","alterations":" EGFR mutation • MET positive","tags":["EGFR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e EGFR mutation • MET positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e erlotinib • onartuzumab (RG3638)"],"overall_status":"Completed","enrollment":" Enrollment 530","initiation":"Initiation: 01/22/2014","start_date":" 01/22/2014","primary_txt":" Primary completion: 01/06/2016","primary_completion_date":" 01/06/2016","study_txt":" Completion: 01/06/2016","study_completion_date":" 01/06/2016","last_update_posted":"2017-03-14"},{"id":"8ff6706a-076e-4c92-932d-088ca0828e2d","acronym":"","url":"https://clinicaltrials.gov/study/NCT01186991","created_at":"2021-01-18T04:44:47.430Z","updated_at":"2024-07-02T16:37:26.364Z","phase":"Phase 2","brief_title":"Study Evaluating the Safety and Efficacy of Onartuzumab And/or Bevacizumab in Combination With Paclitaxel in Participants With Metastatic, Triple Negative Breast Cancer","source_id_and_acronym":"NCT01186991","lead_sponsor":"Genentech, Inc.","biomarkers":" HER-2 • ER • PGR","pipe":" | ","alterations":" HER-2 negative","tags":["HER-2 • ER • PGR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 negative"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Avastin (bevacizumab) • paclitaxel • onartuzumab (RG3638)"],"overall_status":"Completed","enrollment":" Enrollment 185","initiation":"Initiation: 03/01/2011","start_date":" 03/01/2011","primary_txt":" Primary completion: 03/01/2016","primary_completion_date":" 03/01/2016","study_txt":" Completion: 03/01/2016","study_completion_date":" 03/01/2016","last_update_posted":"2017-01-20"},{"id":"67ea7679-0dc0-4de8-8a9d-f876216baefc","acronym":"","url":"https://clinicaltrials.gov/study/NCT01974258","created_at":"2021-01-18T08:59:10.858Z","updated_at":"2024-07-02T16:37:27.922Z","phase":"Phase 1","brief_title":"Safety, Tolerability, and Pharmacokinetics of Onartuzumab Combined With Vemurafenib and/or Cobimetinib in Cancer Patients","source_id_and_acronym":"NCT01974258","lead_sponsor":"Hoffmann-La Roche","biomarkers":" KRAS • BRAF","pipe":" | ","alterations":" KRAS mutation • BRAF V600","tags":["KRAS • BRAF"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e KRAS mutation • BRAF V600"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Zelboraf (vemurafenib) • Cotellic (cobimetinib) • onartuzumab (RG3638)"],"overall_status":"Withdrawn","enrollment":"","initiation":"Initiation: 02/01/2014","start_date":" 02/01/2014","primary_txt":" Primary completion: 07/01/2014","primary_completion_date":" 07/01/2014","study_txt":" Completion: 07/01/2014","study_completion_date":" 07/01/2014","last_update_posted":"2016-11-02"},{"id":"bab0d2e3-cdf6-489a-8032-a35d5a508aea","acronym":"","url":"https://clinicaltrials.gov/study/NCT01662869","created_at":"2021-01-18T07:11:05.853Z","updated_at":"2024-07-02T16:37:27.962Z","phase":"Phase 3","brief_title":"A Study of Onartuzumab in Combination With mFOLFOX6 in Participants With Metastatic HER2-Negative and MET-Positive Gastroesophageal Cancer","source_id_and_acronym":"NCT01662869","lead_sponsor":"Hoffmann-La Roche","biomarkers":" HER-2","pipe":" | ","alterations":" MET positive","tags":["HER-2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e MET positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e 5-fluorouracil • oxaliplatin • leucovorin calcium • onartuzumab (RG3638)"],"overall_status":"Completed","enrollment":" Enrollment 564","initiation":"Initiation: 11/01/2012","start_date":" 11/01/2012","primary_txt":" Primary completion: 12/01/2015","primary_completion_date":" 12/01/2015","study_txt":" Completion: 12/01/2015","study_completion_date":" 12/01/2015","last_update_posted":"2016-11-02"},{"id":"fd8288be-7833-438d-8c8c-1b1bc38ec63d","acronym":"NCT01456325","url":"https://clinicaltrials.gov/study/NCT01456325","created_at":"2021-01-18T06:02:56.908Z","updated_at":"2024-07-02T16:37:27.965Z","phase":"Phase 3","brief_title":"A Study of Onartuzumab (MetMAb) in Combination With Tarceva (Erlotinib) in Participants With Met Diagnostic-Positive Non-Small Cell Lung Cancer Who Have Received Chemotherapy For Advanced or Metastatic Disease (MetLung)","source_id_and_acronym":"NCT01456325 - NCT01456325","lead_sponsor":"Genentech, Inc.","biomarkers":" EGFR","pipe":" | ","alterations":" EGFR mutation","tags":["EGFR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e EGFR mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e erlotinib • onartuzumab (RG3638)"],"overall_status":"Completed","enrollment":" Enrollment 494","initiation":"Initiation: 01/01/2012","start_date":" 01/01/2012","primary_txt":" Primary completion: 01/01/2016","primary_completion_date":" 01/01/2016","study_txt":" Completion: 01/01/2016","study_completion_date":" 01/01/2016","last_update_posted":"2016-11-02"},{"id":"1fc95c0b-cc55-4d4b-8179-c3fda9b72311","acronym":"","url":"https://clinicaltrials.gov/study/NCT01496742","created_at":"2021-01-18T06:16:20.898Z","updated_at":"2024-07-02T16:37:28.921Z","phase":"Phase 2","brief_title":"A Study of Onartuzumab (MetMAb) in Combination With Bevacizumab (Avastin) Plus Platinum And Paclitaxel or With Pemetrexed Plus Platinum in Patients With Non-Squamous Non-Small Cell Lung Cancer","source_id_and_acronym":"NCT01496742","lead_sponsor":"Genentech, Inc.","biomarkers":" EGFR","pipe":"","alterations":" ","tags":["EGFR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Avastin (bevacizumab) • cisplatin • carboplatin • paclitaxel • pemetrexed • onartuzumab (RG3638)"],"overall_status":"Completed","enrollment":" Enrollment 259","initiation":"Initiation: 04/01/2012","start_date":" 04/01/2012","primary_txt":" Primary completion: 11/01/2015","primary_completion_date":" 11/01/2015","study_txt":" Completion: 11/01/2015","study_completion_date":" 11/01/2015","last_update_posted":"2016-09-23"},{"id":"17a1dea1-0fb8-4a32-a738-1325a81c4bdc","acronym":"","url":"https://clinicaltrials.gov/study/NCT01519804","created_at":"2021-01-18T06:23:27.680Z","updated_at":"2024-07-02T16:37:29.370Z","phase":"Phase 2","brief_title":"A Study of Onartuzumab (MetMAb) Versus Placebo in Combination With Paclitaxel Plus Platinum in Patients With Squamous Non-Small Cell Lung Cancer","source_id_and_acronym":"NCT01519804","lead_sponsor":"Genentech, Inc.","biomarkers":" EGFR","pipe":"","alterations":" ","tags":["EGFR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cisplatin • carboplatin • paclitaxel • onartuzumab (RG3638)"],"overall_status":"Completed","enrollment":" Enrollment 108","initiation":"Initiation: 04/01/2012","start_date":" 04/01/2012","primary_txt":" Primary completion: 01/01/2014","primary_completion_date":" 01/01/2014","study_txt":" Completion: 09/01/2015","study_completion_date":" 09/01/2015","last_update_posted":"2016-09-02"},{"id":"5a93b740-6910-4d00-b8f2-72cf65ee8680","acronym":"","url":"https://clinicaltrials.gov/study/NCT01590719","created_at":"2021-01-18T06:47:29.333Z","updated_at":"2024-07-02T16:37:29.936Z","phase":"Phase 2","brief_title":"A Study of Onartuzumab (MetMAb) in Combination With mFOLFOX6 in Patients With Metastatic Human Epidermal Growth Factor Receptor 2 (HER2) Negative Gastroesophageal Cancer","source_id_and_acronym":"NCT01590719","lead_sponsor":"Hoffmann-La Roche","biomarkers":" HER-2","pipe":" | ","alterations":" MET positive","tags":["HER-2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e MET positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e 5-fluorouracil • oxaliplatin • leucovorin calcium • onartuzumab (RG3638)"],"overall_status":"Completed","enrollment":" Enrollment 123","initiation":"Initiation: 07/01/2012","start_date":" 07/01/2012","primary_txt":" Primary completion: 10/01/2014","primary_completion_date":" 10/01/2014","study_txt":" Completion: 10/01/2014","study_completion_date":" 10/01/2014","last_update_posted":"2016-08-09"}]